Iterum Therapeutics Q3 2025: ORLYNVAH launch nets $0.4M revenue; cash runway extended to Q2 2026

Iterum Therapeutics plc

2025-Q3 EPS reported -$0.51 revenue$390,000

Net product revenue of $0.4M from ORLYNVAH launch in August 2025; 2026 sales guidance $5M-$15M.
Cash and equivalents $11.0M as of Sep 30, 2025; additional $2.6M raised Oct-Nov 2025 extends runway into Q2 2026.
GAAP net loss $9.0M ($0.81 diluted EPS); non-GAAP net loss $7.3M vs. $6.1M and $4.8M in Q3 2024.
SG&A expenses rose to $6.5M from $1.8M YoY due to commercialization; R&D fell to $1.3M.
Granted patents in China and Mexico covering sulopenem combinations; IDWeek posters presented.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-281531
form_type: 8-K
ticker: ITRMF
cik: 0001659323
company_name: Iterum Therapeutics plc
filed_at: 2025-11-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.065372+00:00
generated_at: 2026-05-16T19:52:21.063059+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-281531
json_url: https://secwatch.observer/filing/0001193125-25-281531.json
markdown_url: https://secwatch.observer/filing/0001193125-25-281531.md
text_url: https://secwatch.observer/filing/0001193125-25-281531.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/0001193125-25-281531-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1659323/000119312525281531/itrm-20251114.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-281531

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.